Review Maps Interventions That Shift Epigenetic Aging Clocks

The review, published in Frontiers in Genetics, systematically mapped human studies that measured effects on next-generation DNA methylation-based epigenetic aging clocks, identifying 41 studies that met their criteria (Frontiers in Genetics; PR NewsWire). The published evidence map lists interventions that showed statistically favorable changes in at least one next-generation clock, including semaglutide, omega-3 fatty acids, plant-rich dietary patterns, exercise, pitavastatin, caloric restriction, and several supplement interventions, as summarized by the authors and by PR NewsWire coverage (Frontiers; PR NewsWire; News-Medical). The authors made underlying tables available via a Frontiers/figshare dataset that enumerates trial details and clock outcomes (Frontiers, figshare).

Editorial analysis: Next-generation epigenetic clocks are machine-learning models trained to predict biological aging, mortality risk, and healthspan from DNA methylation patterns rather than just chronological age. The review focuses specifically on these next-generation clocks because they are more closely associated with clinical outcomes than first-generation chronological-age predictors, a distinction emphasized in the paper (Frontiers). The review does not claim clinical validation of these clocks as surrogate endpoints; News-Medical and the Frontiers article explicitly state that clock shifts are investigational and do not prove whole-body age reversal (News-Medical; Frontiers).

Editorial analysis: For researchers and practitioners working with biomarker models, the paper provides a consolidated dataset on how diverse human interventions move epigenetic-clock outputs. That dataset can inform choices about endpoints, sample-size expectations, and sensitivity analyses when designing trials that use methylation clocks as exploratory biomarkers. However, the evidence map also highlights heterogeneity in study designs, interventions, and clock versions, which complicates cross-study interpretation (Frontiers).

For practitioners: key open questions include whether clock changes predict downstream clinical benefits, which clock versions are most robust to intervention heterogeneity, and how confounders such as disease status, medication, and cell-type composition were controlled across studies. Observers should watch for randomized trials that predefine methylation-clock endpoints and for meta-analyses that harmonize clock versions and covariates to assess reproducibility (Frontiers; News-Medical).